To determine the incidence and clinical relevance of active human herpesvirus 6 (HHV-6) infection, 92 consecutive unselected recipients of autologous or allogeneic stem cell grafts were investigated in a prospective longitudinal study. Active infection was assessed by the presence of viral deoxyribonucleic acid (DNA) in 846 peripheral blood mononuclear cell specimens and 115 plasma specimens, by means of a specially developed polymerase chain reaction designed to avoid detection of latent genome. The incidence of HHV-6 infection observed was 42.5%, irrespective of the type or source of graft, and infection was significantly associated with partial ( ) or total myelosuppression ( ) and fever ( ). Infusion P p .002 P p .01 P ! .000001 of bone marrow as the source of graft, reactivation occurring before platelet or neutrophil engraftment, and presence of HHV-6 DNA in plasma were identified as risk factors for symptomatic HHV-6 infection ( ).
the presence of active infection. Of the 3 available methods by which active infection can be diagnosed, isolation in cell cultures takes 5-21 days and may be too difficult and costly for routine use. Serology is of limited use in the context of immunosuppression. The detection of HHV-6 DNA, by means of PCR, in peripheral blood would therefore appear to be the most promising laboratory test, since it is easily adaptable to routine laboratory use. Technical procedures, however, need to be adjusted to allow for sufficient discrimination between latent and active infection.
The aim of this prospective longitudinal study of 92 consecutive unselected patients was to evaluate the incidence and clinical relevance of active HHV-6 infection, as assessed by the presence of viral DNA in peripheral blood mononuclear cells (PBMC) or plasma, after either autologous or allogeneic stem cell transplantation.
Patients and Methods
Patients and study design. From January 1997 through January 1998, 92 consecutive and unselected patients who were undergoing allogeneic (28 patients) or autologous (64 patients) stem cell transplantation at Nantes University Hospital, Nantes, France, were enrolled in this prospective longitudinal study. Patient characteristics are shown in table 1.
Patients were examined for active HHV-6 infection once during the 20 days preceding transplantation and either once a week or twice a month during the first 100 days after transplantation (postprocedure follow-up period ranged from 28 to 200 days; median, 93 days). At each follow-up point, PBMC were tested for the presence of HHV-6 DNA. If 2 consecutive PBMC samples were found to be positive by means of PCR, plasma samples were also tested for HHV-6 DNA.
During the follow-up period, the following symptoms potentially cells/L), or anemia (hemoglobin 9 ϫ10 level, !85 g/L) after engraftment; pneumonitis with negative microbiology on bronchoalveolar lavage; and CNS involvement.
GVHD prophylaxis consisted of the standard combination of cyclosporin A and methotrexate; active GVHD was treated with steroids (2 mg/kg/day). Antiviral therapy consisted of acyclovir given either for herpes simplex virus reactivation (15 mg/kg/day) or as CMV prophylaxis in CMV-seropositive allogeneic transplant recipients (500 mg/m 2 t.i.d.) [5] . Ganciclovir treatment (5 mg/kg b.i.d. for 2-3 weeks) was started after the second positive result of testing for CMV DNAemia [6] .
Definitions. "Active HHV-6 infection" was defined as the presence of HHV-6 DNA in PBMC. "Neutrophil engraftment" was defined as an absolute neutrophil count of 1 cells/L, and 9 1 ϫ 10 "platelet engraftment" was defined as a platelet count of 1 cells/L for 2 consecutive days, in the absence of platelet 9 25 ϫ 10 transfusion. GVHD was diagnosed and scored according to organ injury [7] and was confirmed by biopsy.
Serology. The HHV-6 serostatus of recipients was determined during the pretransplantation period by means of ELISA (HHV-6 IgG EIA; Biotrin, Dublin) performed according to the manufacturer's recommendations. Immunologic status for CMV, Epstein-Barr virus, and herpes simplex virus was assessed by use of the tests current in our laboratory (Enzygnost alpha-method; DadeBehring, Frankfurt, Germany).
HHV-6 DNA detection and typing. To avoid false-positive results caused by DNA contamination, rigorous experimental procedures, including the use of separate rooms for the handling of DNA samples, the preparation of aliquots of the PCR mixture, and the analysis of PCR products, were observed. DNA was extracted from PBMC and plasma obtained from EDTA-anticoagulated blood samples. PBMC were collected by means of density gradient centrifugation (Ficoll-hypaque; Eurobio, Les Ullis, France), were counted, and were resuspended in PBS at the adjusted concentration of PBMC/mL. DNA was then ex- 6 2 ϫ 10 tracted by means of a rapid thawing-boiling technique. A total of 100 mL of the plasma specimen was treated with 100 mL of lysis buffer (20 mM mM proteinase K and 0.5% Tris ϩ 5 EDTA ϩ 1% SDS) at 56ЊC for 1 h, and proteinase K was then inactivated at 95ЊC for 10 min. All amplifications were run on supernatants.
HHV-6 DNA from both variants was amplified by PCR with consensus primers, and the amplified products were then developed and typed by means of variant-specific oligonucleotide hybridization. Sequences of primers and probes, located in the large tegument protein gene in the HHV-6 genome, were adapted from previously published data [8] (table 2) . Amplifications were run for 40 cycles (30 s at 94ЊC, 60 s at 60ЊC, and 60 s at 72ЊC) on 2 mL of DNA extract in 23 mL of mixture (1.5 mM MgCl 2 , 200 mM each dNTP, 1 mM each primer P1 and P2, and 0.625 U of Taq polymerase). Colorimetric plate hybridization was done by use of a DNA EIA (GEN-ETIK-DEIA; DiaSorin, Saluggia, Italy), as previously described [9] . Hybridizations were run at 50ЊC with 80 ng of each probe (probes PA and PB) per mL. Two positive controls (DNA extracts corresponding to the variant A TAN strain and the variant B HST strain; donated by J. T. Aubin, Laboratoire de Virologie, Hopital Pitié-Salpétrière, Paris) and a negative control (sterile water) were systematically included in each set of amplification procedures.
The specificity of amplification was assessed by the absence of detection of other herpesviruses. Amplifications of serial dilutions of the 2 positive controls, by use of both our own procedure and the variant-specific primer PCR described by Aubin et al. [8] , yielded the same detection threshold (TCID[50], 10 Ϫ4 to 10 Ϫ5 ). Samples. A total of 846 EDTA-treated blood samples were collected for HHV-6 DNA testing in PBMC, and 115 were collected for testing in plasma. Between 3 and 22 sequential PBMC samples (median, 9 samples) were analyzed for each patient. Between 2 and 10 plasma specimens (median, 3 samples), obtained at the same time as positive PBMC samples, were also tested for 26 patients.
Forty PBMC specimens from healthy persons were also collected to assess the prevalence of HHV-6 DNA in an immunocompetent context. No attempt to isolate HHV-6 from skin was made for patients with a cutaneous rash.
Statistical analysis. Data were analyzed by use of the Epi Info computer database, version 6.04 b (Centers for Disease Control and Prevention, Atlanta). Univariate analysis was done using either the x 2 test or the 2-tailed Fisher exact test, for proportion, and either the F test or the Kruskal-Wallis nonparametric test, for means (analysis of variance). Plausible biological and clinical risk factors for HHV-6 infection were also evaluated by means of logistic regression analysis; factors that were significant at P p .1 were retained in the model (EGRET; Statistics and Epidemiology Research, Seattle). In all cases, the CI was 95%; values of P ! were considered significant. .05
Results

Virological data during active HHV-6 infection.
Of the 846 PBMC samples analyzed for HHV-6 DNA (526 from recipients of autologous and 320 from recipients of allogeneic stem cell transplants), 18.3% (99 from recipients of autologous and 56 from recipients of allogeneic stem cell transplants) yielded positive results. All HHV-6 strains were typed as B variants. The incidence of active HHV-6 infection was 42.5%, after both autologous (27/64 patients) and allogeneic (12/28 patients) transplantation. No significant difference was noted with regard to either the source of stem cells (bone marrow vs. peripheral blood stem cells) or pretransplantation HHV-6 serostatus.
Among the 39 patients with active HHV-6 infection, the onset of such infection occurred 6-117 days after transplantation (median, 17 days). The first positive PCR result was observed earlier among patients receiving autologous transplants than among those receiving allogeneic recipients (table 3). Seven of the 39 patients with active infection had a single isolated positive PCR result on PBMC, and active infection started later after transplantation ( ). For the 32 remaining infected P p .01 patients (9 allogeneic and 23 autologous transplant recipients), the median duration of active infection was 24 days (range, 7-194 days); 21 patients were still positive at the end of the study, and 2 experienced only sporadic PCR-positive episodes. Of the 26 patients whose plasma was also examined for HHV-6 DNA, 46% proved to be positive (table 3) : PCR yielded positive results for 20 of 115 specimens, and the onset of plasma DNAemia coincided with the first positive PCR result for PBMC (median delay, 0 days; range, 0-17 days). None of the PBMC samples obtained from healthy persons or patients before transplantation were positive for HHV-6 DNA.
HHV-6 infection: clinical and biological associations. For evaluation of the consequences of active HHV-6 infection, the occurrence of symptoms presumed to be related to HHV-6 was compared in infected patients (during the period of positive PCR results for PBMC) and uninfected subjects (table 4) . The symptoms most evocative of HHV-6 infection were hyperthermia and/or thrombocytopenia and/or anemia. The negative predictive value of PCR analysis of PBMC for the occurrence of these events was always 10.77, and it reached 0.96 when all 3 symptoms were observed together. Positive predictive values of the occurrence of fever, anemia, or thrombocytopenia were 0.74, 0.42, and 0.56, respectively (and were 0.88, 0.48, and 0.59, respectively, after elimination of isolated positive PCR results), and they fell to !0.50 if 12 of these events occurred. The 5 patients who experienced pancytopenia after engraftment were all actively infected.
Delayed neutrophil and platelet engraftment was noted in the group of infected patients (table 4); there were no differences that could be ascribed to the source of stem cell or the type of graft. Moreover, among patients who developed active infection before engraftment, the median duration of neutrophil aplasia (in 19 patients) and platelet aplasia (in 21 ). Again, no differences were noted with regard to the type .002 or source of graft. In the infected population as a whole, we did not observe any significant association with cutaneous rash or pulmonary signs (table 4).
The incidence of acute GVHD in allogeneic stem cell transplant recipients was not correlated with active HHV-6 infection, which occurred in 7 of the 15 patients with a GVHD grade у1 versus 5 of the 13 patients without GVHD ( ). However, P 1 .05 the incidence of HHV-6 infection was higher in patients who developed severe acute GVHD (grade, у3): Among the 6 patients with severe GVHD, 5 were determined to be positive for HHV-6 by means of PCR analysis, whereas among the 9 patients with nonsevere GVHD, 2 had active infection ( ). P p .04 HHV-6 infection occurred before GVHD in 3 patients, after GVHD in 3 other patients, and concomitantly in 1 patient.
CMV active infection developed in 4 of the 8 CMV-seropositive allogeneic stem cell transplant recipients. These 4 patients were the only ones who had active HHV-6 infection. CMV DNAemia was first detected in blood 10-30 days after the onset of active HHV-6 infection. At initiation of ganciclovir preemptive therapy, PCR results for HHV-6 were negative in 3 patients. In the remaining patient, HHV-6 DNA was cleared from plasma but not from PBMC during administration of ganciclovir.
Prognostic factors. The following variables were considered to be biologically or clinically plausible risk factors for the occurrence of active infection and were evaluated in a logistic regression model: sex, age, type and source of graft, underlying disease, conditioning regimen, and the recipient's HHV-6, CMV, Epstein-Barr virus, and herpes simplex virus serostatus. No independent risk factors were identified.
During evaluation of the probability of the development of symptoms presumed to be related to HHV-6 during active infection, 2 associated factors were identified. The infusion of bone marrow as the source of graft was associated, in all patients, with hyperthermia during infection ( ). Thrombocytopenia P p .006 and/or anemia, regardless of whether they were associated with fever, also occurred more frequently ( ; RR, 4.40 [95% CI, P ! .01 1.13-17.07] for thrombocytopenia and 3.15 [95% CI, 1.19-8.34] for anemia). There was no difference in these respects between allogeneic and autologous transplantation. In addition, the detection of HHV-6 DNA in plasma was more frequently associated with thrombocytopenia only ( ) or with thrombocyto-P p .009 penia and fever ( ). Positive predictive values for PCR P p .005 on plasma were consequently higher than those for PCR on PBMC, reaching 1 and 0.91, respectively, for fever and thrombocytopenia.
Discussion
In this longitudinal study of 92 unselected recipients of bone marrow or peripheral blood stem cell transplants, we demonstrated a 42.5% incidence of active HHV-6 infection in the context of both allogeneic and autologous transplantation. Our data were obtained with a specially developed 1-step PCR that was designed to avoid detection of latent genome and that is easily adaptable to routine laboratory use, thanks to rapid DNA extraction and a colorimetric plate hybridization method suitable for automation. Our results are consistent with those of previous studies that have estimated the incidence of active infection, as detected by positive culture, to be 0 prior to allogeneic bone marrow transplantation and 37%-46% afterward [10] [11] [12] . Moreover, our PCR failed to detect any HHV-6 DNA in PBMC from immunocompetent persons. This allows us to conclude that our PCR methodology could be of potential use as an indicator of active infection.
Our findings were only weakly in agreement with those of other studies, which used a nested PCR for diagnosis of active infection. Such studies found that 20%-40% of allogeneic bone marrow transplant recipients had positive PCR results during the pretransplantation period and that 70%-100% had positive results after transplantation [13] [14] [15] [16] . In addition, the incidence of isolated positive PCR results in our study was lower than that which is usually reported [13, 15] . These discrepancies may be due to methodological differences; for example, the highly sensitive nested PCR procedures run on larger numbers of PBMC in these 4 studies may have detected latent genome in lymphocytes, which have been identified as one of the preferential sites for both latent and active infection in peripheral blood [3] . Conversely, the low incidence of active HHV-6 infection (4%) reported by Chan et al. [17] could be explained by the fact that dextran was used to remove peripheral blood leukocytes, a method that enhances the proportion of polymorphonuclear leukocytes [18] .
As previously reported in a small number of studies, we found no statistically significant difference in the incidence of HHV-6 active infection when allogeneic bone marrow transplantation was compared with autologous bone marrow transplantation [12, 13] or when allogeneic bone marrow transplantation was compared with allogeneic peripheral blood stem cell transplantation [19] .
The virological characteristics of active infection identified in our study correlate well with most of the published data. Not surprisingly, all virus strains were typed as B variants [20] , because analysis was performed on PBMC [21] . We confirmed that active HHV-6 infection occurs early after transplantation, at approximately week 3 or week 4 for most patients [10, 15, 16, 19] . The earlier onset of infection in the autologous context could not be explained by differences in the conditioning regimen (total body irradiation vs. no total body irradiation) or in the source of stem cells. It should be noted, however, that only small numbers of patients received autologous bone marrow transplants or allogeneic peripheral blood stem cell transplants. The median duration of active infection (24 days) was longer than that which was previously reported in the 2 studies that used culture methods to assess this particular point [10, 12] , and it was not significantly affected by any of the parameters evaluated in our study.
Pretransplantation HHV-6 serostatus yielded no information about the risk of active HHV-6 infection developing [22] . As already described in a large epidemiological study of immunocompetent subjects (reviewed in [3] ), we observed in our population a decline in seroprevalence with age. This may reflect a loss of specific anti-HHV-6 antibodies, which became undetectable with current serological tests. Consequently, we postulate that the HHV-6 serostatus of the recipient did not allow for reactivation to be distinguished from primary infection, especially in this context of immunosuppression.
The significance of the isolated positive PCR results observed for 7 of the patients enrolled remains unclear because of the low incidence of such results. However, we did show that the finding of at least 2 consecutive positive PCR results increases their predictive value for the occurrence of symptoms related to HHV-6, as previously observed for CMV in bone marrow transplantation [6] .
It is particularly difficult to compare our clinical and laboratory data with those of other published series, which have produced somewhat conflicting results. Most of these series involved smaller numbers of patients, some of whom were selected on the basis of CMV serostatus [16] , occurrence of an unexplained fever [11] , or bone marrow suppression [23] . In studies of fewer or unselected patients [12-15, 17, 19] , active infection was diagnosed by means of various tools, and the clinical and laboratory events that were analyzed were not homogeneous. Because of a large disparity between the doses used for and timing of acyclovir administration during our study and the small number of patients receiving ganciclovir, no information on their effect on HHV-6 could be deduced.
Our study highlights the frequent association of active infection with fever and with partial or total myelosuppression, irrespective of the allogeneic or autologous context. We found more suppression of erythroid and megakaryocyte lineages, which correlates well with some studies carried out in vitro [24, 25] . The contribution of active HHV-6 infection to GVHD is still controversial [12, 15, 17] . We observed an increased severity of GVHD in actively infected patients [13, 14, 19 ], but we could deduce from our study no argument that might determine whether active HHV-6 infection enhances GVHD or whether it is the consequence of GVHD therapy [15] . Finally, we observed, as previously observed in solid organ transplant recipients [26] [27] [28] , a relationship between active HHV-6 infection and the subsequent development of active CMV infection in CMV-seropositive allogeneic stem cell transplant recipients.
Infusion of bone marrow, which was among the factors that could promote presumed HHV-6 disease during active infection, led to an increased risk of myelosuppression and fever. We have also shown that early onset of infection, particularly before neutrophil or platelet engraftment, increased the severity of symptoms that can be ascribed to HHV-6, because the majority of undiagnosed pulmonary signs or cutaneous rashes were observed during this period. Finally, we found that a positive PCR result for plasma is the most specific marker for the occurrence of thrombocytopenia and/or fever, although it is less sensitive. This marker has already been proposed for use in the selective diagnosis of active infection in studies involving a limited number of patients [29, 30] and, potentially, as previously demonstrated for CMV [31] , as a marker of HHV-6 disease [17] . Presence of HHV-6 DNA in plasma may probably reflect a higher virus load, but whether plasma HHV-6 DNA originates from the lysis of infected lymphocytes by the immune response [29] remains unclear, because the incidence of positive PCR results for plasma was similar in autologous and the more immunosuppressed allogeneic recipients.
The results of this prospective longitudinal study, performed on a large number of patients, show that the adaptation of technical procedures for PCR can allow for the detection of true active infections. Although no mortality or severe clinical events attributable to HHV-6 were recorded in our study, active infection could result in an increased morbidity in both allogeneic and autologous bone marrow and peripheral blood stem cell transplant recipients, particularly because of its myelosuppressive effect. Prospective evaluation in multicenter studies is now needed to confirm our data and to evaluate the potential benefit of treating active infection, especially when it occurs in patients with an increased risk of HHV-6 disease, such as those for whom bone marrow was the source of stem cells, those in whom early reactivation has occurred before transplantation, or those in whom HHV-6 DNA is present in plasma specimens.
